



October 6, 2016

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra East,
Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400023

Scrip Code: JUBILANT

Scrip Code: 530019

Dear Sir/Madam,

Sub: Issue of unsecured high yield bonds by our wholly-owned subsidiary Jubilant Pharma Limited (a company incorporated under the laws of Singapore), outside India, under Regulation S of the U.S. Securities Act of 1933 (the “US Securities Act”).

Pursuant to Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), which requires a listed entity to disclose all events or information with respect to subsidiaries which are material for the listed entity and in furtherance of our letter dated September 23, 2016, we wish to inform you that we have been informed that Jubilant Pharma Limited, Singapore ('JPL'), our wholly-owned subsidiary, has successfully completed today i.e. October 6, 2016, a debut issuance, under Regulation S of the U.S. Securities Act of 1933, of its rated unsecured high yield bonds (the 'Notes') bearing interest at 4.875% per annum. The Notes were issued at par in a principal amount of US\$300 million and will mature in October 2021.

JPL has been rated BB- by Standard & Poor's Ratings Services ('S&P') and Fitch Inc. ('Fitch') and the Notes have been rated BB- by S&P and BB by Fitch. The Notes will be listed and quoted on the Official List of the Singapore Exchange Securities Trading Limited (the 'SGX-ST').

The net proceeds of the Notes shall be used (a) to prepay the existing debts of JPL and its subsidiaries; (b) for upstreaming up to US\$50 million to Jubilant Life Sciences Limited for prepayment of its existing debts and (c) for general corporate purposes.

A Jubilant Bharti Company

OUR VALUES



Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624



The Joint Lead Managers to the issue were Citigroup Global Markets Singapore Pte. Ltd., Credit Suisse (Hong Kong) Limited, DBS Bank Ltd., The Hongkong and Shanghai Banking Corporation Limited and J.P. Morgan (S.E.A.) Limited.

The above is for your information and records.

Thanking You,

Yours Sincerely,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary